| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 4 | 13 | +0,11 % | ||
| BIOGEN | 1 | 54 | -0,84 % | ||
| MODERNA | 1 | 16 | +0,12 % | ||
| COMPASS PATHWAYS | 1 | 11 | 0,00 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +2,30 % | ||
| AMGEN | - | 27 | +0,03 % | ||
| INCYTE | - | 25 | -0,60 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | -0,82 % | ||
| MONTE ROSA THERAPEUTICS | - | 21 | +5,95 % | ||
| EYEPOINT | - | 20 | -3,94 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:06 | Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis' | 1 | Benzinga.com | ||
| 09:50 | Sonntag-Meldung zu BIONTECH SE ADR: Jetzt nicht zögern! | 1 | Maximilian Berger | ||
| 09:30 | ANALYSE: Curevac - Was hinter den Kulissen passiert - So reagieren erfahrene Anleger jetzt | Hebelschein-Spekulant | |||
| 09:22 | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | Small- & Micro Cap Investment | |||
| 06:30 | Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study | 347 | AFX News | PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest... ► Artikel lesen | |
| Sa | Compass Pathfinder Limited: Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments | 612 | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical... ► Artikel lesen | |
| Sa | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | 23 | Seeking Alpha | ||
| Sa | Sanofi: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study | 679 | GlobeNewswire (Europe) | ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the... ► Artikel lesen | |
| Sa | BioNTech Aktie: Kurs dreht auf! Zulassungsantrag, Pipeline-Power und ein Einstiegssignal! | 2.082 | FinanzNachrichten.de | © Foto: Pexels (Symbolbild)Lange war BioNTech für viele Anleger ein Sorgenkind. Der Rückgang des Corona-Geschäfts drückte auf den Kurs, der Abgang der Gründer sorgte für Unsicherheit. Dann kam der Absturz... ► Artikel lesen | |
| Sa | argenx SE: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | 2 | GlobeNewswire (USA) | ||
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 10 | GlobeNewswire (USA) | ||
| Fr | Revolution Medicines raises $2.1B in stock and debt offerings | 1 | Investing.com | ||
| Fr | ORIC presents preclinical data on prostate cancer drug at AACR | 1 | Investing.com | ||
| Fr | Revolution Medicines beschafft 2,1 Mrd. US-Dollar über Aktien- und Anleiheemissionen | 4 | Investing.com Deutsch | ||
| Fr | ORIC Pharmaceuticals präsentiert präklinische Daten zu Prostatakrebs-Wirkstoff auf AACR-Tagung | 1 | Investing.com Deutsch | ||
| Fr | Pyxis Oncology legt vielversprechende präklinische Daten für MICVO bei Kopf- und Halskrebs vor | 4 | Investing.com Deutsch | ||
| Fr | Nuvalent presents zidesamtinib data in pre-treated lung cancer | 1 | Investing.com | ||
| Fr | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| Fr | ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| Fr | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | 1 | GlobeNewswire (USA) |